CBSA and Hogan Lovells bring you 2021’s Regulatory Symposium in four virtual sessions every Thursday from 9:00—10:00am MT starting in July.

Topics include:

• July 15: Employment Issues and Returning to Work – Including Mandatory Vaccinations
  Speakers: Michael E. DeLarco, Office Managing Partner (New York), Hogan Lovells, and Eleanor deGolian Kasper, Associate (Colorado Springs), Hogan Lovells
• July 22: The Future of Litigation – Prep Act, Government Authorizations, and Liability
  Speakers: Michael C. Theis, Partner (Denver), Hogan Lovells, and Emily Lyons, Senior Associate (Washington, D.C.), Hogan Lovells
• July 29: FDA Emergency Use Authorization and the Transition Back to Normal Health Approvals – A Look at the Next 9-18 Months (End of Public Health Declaration)
  Speakers: Jodi Scott, Partner (Denver), Hogan Lovells and Wil Henderson, Senior Associate (Denver), Hogan Lovells
• August 5: Digital Health and its Evolution Since the Beginning of COVID-19
  Speakers: Brooke Bumpers, Counsel (Washington, D.C.), Hogan Lovells and Lowell Zeta, Counsel (Washington, D.C.), Hogan Lovells and TBA

Complete Four-Session Series: Complimentary to CBSA Members/$25 Non Members
Please select all sessions you wish to attend on the registration page.

Session Details

August 5: Digital Health and its Evolution Since the Beginning of COVID-19
Speakers: Brooke Bumpers, Counsel (Washington, D.C.), Hogan Lovells and Lowell Zeta, Counsel (Washington, D.C.), Hogan Lovells and TBA

This presentation on digital health and its evolution since the beginning of the COVID-19 pandemic will address the wide range of ways digital health technologies have been implemented or expanded, and which of these changes are here to stay.  Almost overnight the use of telehealth services exploded in order to accommodate the need to limit face-to-face interactions, and we’ll address the changes in federal and state regulations, as well as government and commercial payer policies, that were required to accommodate that method of delivering health care services in a wide range of settings. We’ll also talk about the pros and cons of health care delivered through digital technologies, where it works and where it doesn’t, how policymakers are looking to the future of telehealth, and which of these changes necessitated by the pandemic are likely to remain.  The pandemic also had a dramatic effect on clinical trials, and we’ll also address some of the ways the pandemic has accelerated the use of digital technologies health innovation have been implemented in the context of research and patient monitoring, and how the FDA is viewing these changes.

Review in-depth descriptions of each session.